Loading...

Gino In

Title(s)Assistant Professor of Clinical Medicine
AddressNOR 3440 NTT
Health Sciences Campus
Los Angeles CA 90089-9324
Phone+1 323 226 7622
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Southern California, Los Angeles, CAFellowship2016Hematology/Oncology
    SUNY Downstate Medical Center, Brooklyn, NYResidency2011Internal Medicine
    SUNY Downstate Medical Center, Brooklyn, NYInternship2010
    Ross University, North Brunswick Township, NJMD2010Medicine
    Emory University, Atlanta, GAMPH2006Environmental/Occupational Health
    Emory University, Atlanta, GABS2002
    Collapse Awards and Honors
    University of Southern CaliforniaChief Medical Oncology Fellow

    Collapse Overview 
    Collapse Overview
    Gino K. In, MD, MPH, is a medical oncologist who specializes in solid tumor and cutaneous oncology. He completed his fellowship training in hematology and oncology at the University of Southern California, Keck School of Medicine, where he was the chief medical oncology fellow. He subsequently joined the USC Norris Comprehensive Cancer Center, and now serves as Assistant Professor of Clinical Medicine in the Division of Oncology, and Assistant Professor of Dermatology. Dr. In’s research focus includes the multi-disciplinary management of melanoma and other skin cancers, including cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma. He has a specific interest in non-UV related melanoma subtypes and intratumoral therapies. Dr. In is the lead primary investigator for cutaneous oncology clinical trials at USC, including studies through the National Cancer Institute, California Cancer Consortium, and Southwest Oncology Group.

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922). Melanoma Res. 2021 04 01; 31(2):162-172. Moschos SJ, Eroglu Z, Khushalani NI, Kendra KL, Ansstas G, In GK, Wang P, Liu G, Collichio FA, Googe PB, Carson CC, McKinnon K, Wang HH, Nikolaishvilli-Feinberg N, Ivanova A, Arrowood CC, Garrett-Mead N, Conway KC, Edmiston SN, Ollila DW, Serody JS, Thomas NE, Ivy SP, Agrawal L, Dees EC, Abbruzzese JL. PMID: 33661190.
      View in: PubMed   Mentions:    Fields:    
    2. The Time to Offer Treatments for COVID-19. Expert Opin Investig Drugs. 2021 Mar 15. Ngo BT, Marik P, Kory P, Shapiro L, Thomadsen R, Iglesias J, Ditmore S, Rendell M, Varon J, Dubé M, Nanda N, In G, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer DE, Ehresmann G, Peng D, Smogorewski M, Armstrong A, Dasgupta R, Sattler F, Brennan-Rieder D, Mussini C, Mitja O, Soriano V, Peschanski N, Hayem G, Confalonieri M, Piccirillo MC, Lobo-Ferreira A, Bello Rivero I, Turkia M, Vingevoll EH, Griffin D, Hung IF. PMID: 33721548.
      View in: PubMed   Mentions: 1     Fields:    
    3. The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Rev. 2021 02 08. Griffin DO, Brennan-Rieder D, Ngo B, Kory P, Confalonieri M, Shapiro L, Iglesias J, Dube M, Nanda N, In GK, Arkfeld D, Chaudhary P, Campese VM, Hanna DL, Sawcer D, Ehresmann G, Peng D, Smorgorzewski M, Amstrong A, Vinjevoll EH, Dasgupta R, Sattler FR, Mussini C, Mitjà O, Soriano V, Peschanski N, Hayem G, Piccirillo MC, Lobo-Ferreira A, Rivero IB, Hung IFH, Rendell M, Ditmore S, Varon J, Marik P. PMID: 33556957.
      View in: PubMed   Mentions:    Fields:    
    4. 18F-FDG PET/CT Monitoring of Response to Programmed Death Protein 1 Blockade in Metastatic Basal Cell Carcinoma. Clin Nucl Med. 2021 Jan 28. Jadvar H, In GK. PMID: 33512957.
      View in: PubMed   Mentions:    Fields:    
    5. COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study. Endocr Pract. 2021 Feb; 27(2):90-94. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, Su MA, Lechner MG. PMID: 33551317.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Impact of COVID-19 infection among cancer patients treated at the Los Angeles County Medical Center. Cancer Treat Res Commun. 2020 Dec 10; 26:100273. Antrim L, Capone S, Dong S, Chung D, Lin S, Wald-Dickler N, In GK. PMID: 33338856.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2020 Nov 18. In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, Tseng WW, Swanson M, Kokot N, Lang JE, Menendez L, DeClerck B, Kim G, Hu JC, Terando A, Jadvar H, Ricker C, Miller KA, Peng DH, Wysong A. PMID: 33210210.
      View in: PubMed   Mentions:    Fields:    
    8. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood). 2021 Jan; 246(1):31-39. Owsley J, Stein MK, Porter J, In GK, Salem M, O'Day S, Elliott A, Poorman K, Gibney G, VanderWalde A. PMID: 33019809.
      View in: PubMed   Mentions:    Fields:    
    9. Molecular profiling of melanoma brain metastases compared to primary cutaneous melanoma and to extracranial metastases. Oncotarget. 2020 Aug 18; 11(33):3118-3128. In GK, Poorman K, Saul M, O'Day S, Farma JM, Olszanski AJ, Gordon MS, Thomas JS, Eisenberg B, Flaherty L, Weise A, Daveluy S, Gibney G, Atkins MB, Vanderwalde A. PMID: 32913556.
      View in: PubMed   Mentions:    Fields:    
    10. Rapidly Progressive Porocarcinoma of the Ear and Multidisciplinary Approach to Management. Dermatol Surg. 2020 Mar 04. Rabi S, Syder N, Ragab O, In G, Hu JC. PMID: 32141925.
      View in: PubMed   Mentions:    Fields:    
    11. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease. Cancer Med. 2020 02; 9(4):1441-1450. Gatalica Z, Vranic S, Krušlin B, Poorman K, Stafford P, Kacerovska D, Senarathne W, Florento E, Contreras E, Leary A, Choi A, In GK. PMID: 31899853.
      View in: PubMed   Mentions: 4     Fields:    
    12. Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. Int Ophthalmol Clin. 2020; 60(2):77-89. Lu JE, Chang JR, Berry JL, In GK, Zhang-Nunes S. PMID: 32205655.
      View in: PubMed   Mentions:    Fields:    
    13. Prevalence and correlates of adherence to skin examination among adolescent and young adult survivors of melanoma from the Project Forward Study. Pediatr Blood Cancer. 2020 03; 67(3):e28090. Miller KA, Wojcik KY, Cockburn MG, In GK, Hamilton AS, Milam JE. PMID: 31774240.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Concurrent radiation therapy with programmed cell death protein 1 inhibition leads to a complete response in advanced cutaneous squamous cell carcinoma. JAAD Case Rep. 2019 Sep; 5(9):763-766. Vaidya P, Mehta A, Ragab O, Lin S, In GK. PMID: 31516991.
      View in: PubMed   Mentions:
    15. Skin cancer and dermatoses in a majority-Hispanic population of solid organ transplant recipients. J Am Acad Dermatol. 2020 Aug; 83(2):607-610. Adler BL, Smogorzewski J, Sierro T, Shauly O, Osipchuk D, Miller M, Mert M, Fong MW, Ganesh S, Han H, In GK, Maw TT, Smogorzewski M, Hu J, Ngo B, Lee D, Ahronowitz I. PMID: 31400454.
      View in: PubMed   Mentions:    Fields:    
    16. Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation. BMJ Case Rep. 2019 Jun 20; 12(6). Snow A, Ricker C, In GK. PMID: 31227566.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    17. Transcriptional regulation of autophagy-lysosomal function in BRAF-driven melanoma progression and chemoresistance. Nat Commun. 2019 04 12; 10(1):1693. Li S, Song Y, Quach C, Guo H, Jang GB, Maazi H, Zhao S, Sands NA, Liu Q, In GK, Peng D, Yuan W, Machida K, Yu M, Akbari O, Hagiya A, Yang Y, Punj V, Tang L, Liang C. PMID: 30979895.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansAnimalsCells
    18. Cetuximab as a Component of Multimodality Treatment of High-Risk Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis From a Single Tertiary Academic Medical Center. Dermatol Surg. 2019 02; 45(2):254-267. Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, Wysong A. PMID: 30672860.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    19. Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma. JAAD Case Rep. 2018 Nov; 4(10):1004-1006. Lara KM, In GK, Matcuk GR, Mehta A, Hu JS. PMID: 30450405.
      View in: PubMed   Mentions:
    20. Eccrine Porocarcinoma: New Insights and a Systematic Review of the Literature. Dermatol Surg. 2018 10; 44(10):1247-1261. Nazemi A, Higgins S, Swift R, In G, Miller K, Wysong A. PMID: 29894433.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Converg Sci Phys Oncol. 2017 Sep; 3(3). In G, Mason J, Lin S, Newton PK, Kuhn P, Nieva J. PMID: 30283700.
      View in: PubMed   Mentions:
    22. Development of metastatic brain disease involves progression through lung metastases in EGFR mutated non-small cell lung cancer. Convergent Science Physical Oncology. 2017; 3(3). In GK, Mason J, Lin S, Newton P, Kuhn P, Nieva J.
    23. Skin Cancer Prevention Among Hispanics: a Review of the Literature. Epidemiology. 2017. Miller KA, In GK, Jiang SY, Ahadiat O, Higgins S, Wysong A, Cockburn MG.
    24. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. Ther Adv Med Oncol. 2017 Aug; 9(8):533-550. In GK, Hu JS, Tseng WW. PMID: 28794805.
      View in: PubMed   Mentions:
    25. Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors: Current Concepts and Controversies. Urol Clin North Am. 2015 Aug; 42(3):347-57. In G, Dorff T. PMID: 26216822.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Emerging Chemotherapy Agents in Lung Cancer: Nanoparticle Therapeutics for Non-Small Cell Lung Cancer. Transl Cancer Res. 2015; 4(4):340-355. In GK, Nieva J. View Publication.
    Gino's Networks
    Concepts (74)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (46)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (59)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _
    ↑